VolitionRx (VNRX) announces that it has signed an agreement with Hologic Diagenode for the co-marketing of Volition’s Nu.Q Discover service. The Nu.Q Discover service provides drug developers and scientists with a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to being market ready. Under the agreement, Hologic (HOLX) will co-market Nu.Q Discover services of Volition with Hologic Customers for an initial one-year term. If successful, the aim is for Hologic to be appointed as an exclusive provider of those services, subject to further terms being agreed.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNRX:
- VolitionRX’s Strategic Partnership and Growth Potential Drive Buy Rating
- VolitionRx signs first human out licensing deal for APS
- VolitionRx Ltd. Earnings Call: Key Insights and Challenges
- VolitionRx Reports Q2 2025 Financial Results and Strategic Progress
- VolitionRx reports Q2 revenue $400K, consensus $375.72K